RPG LifeScience.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE105J01010
  • NSEID: RPGLIFE
  • BSEID: 532983
INR
2,201.00
-7.3 (-0.33%)
BSENSE

Dec 05

BSE+NSE Vol: 4.61 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About RPG Life Sciences Ltd stock-summary
stock-summary
RPG Life Sciences Ltd
Small Cap
Pharmaceuticals & Biotechnology
RPG Life Sciences Limited, formerly Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited' .
Company Coordinates stock-summary
Company Details
RPG House, 463 Dr Annie Besant Road Worli Mumbai Maharashtra : 400030
stock-summary
Tel: 91-022-24981650
stock-summary
info@rpglifesciences.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 13.23 Cr
Number of Shares
1.65 Cr
Face Value
INR 8.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
17-Oct-2016
1.65
13.23
2910
8
ESOP
17-Oct-2016
1.65
13.23
2910
8
ESOP
23-Jul-2014
1.65
13.23
864
8
ESOP
23-Jul-2014
1.65
13.23
864
8
ESOP
01-Nov-2010
1.65
13.23
28391
8
ESOP
01-Nov-2010
1.65
13.23
28391
8
ESOP
29-Sep-2010
1.65
13.21
1438000
8
Conversion of Warrants
29-Sep-2010
1.65
13.21
1438000
8
Conversion of Warrants
31-Mar-2010
1.51
12.06
700000
8
Conversion of Warrants
31-Mar-2010
1.51
12.06
700000
8
Conversion of Warrants
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 6 Schemes (3.2%)

FIIs

Held by 45 FIIs (1.11%)

Promoter with highest holding

Nucleus Life Trust (mr. Harsh Vardhan Goenka Is A Trustee) (53.94%)

Highest Public shareholder

Authum Investment And Infrastructure Limited (2.02%)

Individual Investors Holdings

15.37%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
H V Goenka
Chairman
2.5 lacs
C L Jain
Non Executive Independent Director
3.95 lacs
Lalit S Kanodia
Non Executive Independent Director
2.6 lacs
Mahesh S Gupta
Non Executive Independent Director
3.79 lacs
Manoj K Maheshwari
Non Executive Independent Director
2.0 lacs
Narendra Ambwani
Non Executive Independent Director
2.64 lacs
Zahabiya Khorakiwala
Non Executive Independent Director
1.55 lacs
Yugal Sikri
Non Executive Independent Director
3.75 lacs
Sachin Nandgaonkar
Non Executive Director
3.1 lacs
C T Renganathan
Managing Director
2.48 cr
Rajesh Shirambekar
Company Secretary
0
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Preparations
323.83
98.08%
Other Operating Revenue - Export Incentives
5.39
1.63%
Other Operating Revenue - Scrap
0.85
0.26%
 
98.08
Pharmaceutical Preparations
1.92
Pharmaceutical Preparations
1.63
Other Operating Revenue - Export Incentives
98.37
Other Operating Revenue - Export Incentives
0.26
Other Operating Revenue - Scrap
99.74
Other Operating Revenue - Scrap
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
182 Cr
(Quarterly Results - Sep 2025)
Net Profit:
37 Cr
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 3,662 Cr (Small Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

1.09%

stock-summary
Debt Equity

-0.40

stock-summary
Return on Equity

20.12%

stock-summary
Price to Book

6.58